KR840009075A - Crf-상사체의 제법 - Google Patents

Crf-상사체의 제법 Download PDF

Info

Publication number
KR840009075A
KR840009075A KR1019840001956A KR840001956A KR840009075A KR 840009075 A KR840009075 A KR 840009075A KR 1019840001956 A KR1019840001956 A KR 1019840001956A KR 840001956 A KR840001956 A KR 840001956A KR 840009075 A KR840009075 A KR 840009075A
Authority
KR
South Korea
Prior art keywords
glu
ala
gln
leu
len
Prior art date
Application number
KR1019840001956A
Other languages
English (en)
Other versions
KR900006559B1 (ko
Inventor
에드워어드 프레드릭 리비어(외 2) 지인
Original Assignee
델버어트 어니스트 그란즈
더솔크 인스티튜트 훠 바이올로지칼스터디이즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 델버어트 어니스트 그란즈, 더솔크 인스티튜트 훠 바이올로지칼스터디이즈 filed Critical 델버어트 어니스트 그란즈
Publication of KR840009075A publication Critical patent/KR840009075A/ko
Application granted granted Critical
Publication of KR900006559B1 publication Critical patent/KR900006559B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Vehicle Body Suspensions (AREA)
  • Control Of Eletrric Generators (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Control Of El Displays (AREA)

Abstract

요약 없음

Description

CRF-상사체의 제법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. (a) 적어도 하나의 보호기를 가진 하기 구조식(Ⅱ)의 펩티드를 생성한 후
    (b) 상기 구조식(Ⅱ)의 펩티드로부터 보호기(들) 또는 고정결합을 분리시키고
    (c) 소망에 따라 결과 생성된 펩티드를 그의 무독성 부가염으로 전환시키는 것으로 구성된 하기 구조식 (I)의 화합물 또는 그의 무독성부가염을 제조하는 방법.
    Y-R1-Pro-Pro-Ile-Ser-R8-R9-Leu-R11-R12-R13-Ieu-Ieu-Arg-R17-
    R18-R19-Glu-R21-R22-R23-R24-R25-R26-R27-R28-R29-Gln-Ala-R32-R33(I)
    -Asn-Arg-R36-R37-R38-R39-R40-R41-NH|2
    X1-R1-Pro-Pro-Ile-Ser(X2)-R8-R9(X5)-Leu-R|11(X2)-R12(X4)-R13(X 또
    는 X5)-Ieu-Ieu-Arg(X3)-R17(X5또는 X6)-R18-R19(X4)-Glu(X5)-R21-R22
    (X2또는 X5)-R23(X3X6)-R24(X4)-R25(X5)-R26(X4또는 X5)-R27(X4또는 X5) (Ⅱ)
    -R28(X6)-Gln(X4)-Gln(X4)-Gln(X4)-ala-R32(X)-R33(X2또는 X4)-Asn
    (X4)-Arg(X3)-R36(X6)-Leu-R38-R39(X|5)-R40(X4)-R41(X4)-
    상기 구조식(I)에서
    Y는 C7이하의 아실기 또는 수소이며; R1은 Ser-Gln-Glu 또는 PGlu-Gly 또는 Gln-Glu 또는 Glu 또는 D-Ser-Gln-Glu 또는 D-Ser-Glu-Glu 또는 Glu-Glu 또는 D-PGlu-Gly 또는 desR1이며; R8R8R12R19및 R24는 len, lle,ala, Gly, Val,Nle,Phe 및 Gln으로 구성된 군으로부터 선택되며; R9은 Asp 또는 Glu이며; R11은 Thr 또는 Ser이며;R13은 His,Tyr또는 Glu이며; R17은 Glu 또는 Lys이며; R18은 Val,Nle 또는 Met 이며;R21은 Met,Nva,Ile,ala,len,Phe,Nle,Vle,Val, 또는 Gln이며;R22은 aLa,Thr,AsP 또는 Glu 이며;R23는 Arg, Orn,Har 또는 Lys이며;R24은 Asp 또는 Glu 이며 R26는 Gln,Asn 또는 Lys이며;R27은 Ien,Ile,ala,Val,Nva,Met,Nle,Phe,Asp,Asn,Gln 또는 Glu이며;R28은 ala,Arg 또는 Lys이며;R29는 Gln 또는 Gln 또는 Glu이며;R32은 His, Gly,Tyr 또는 ala이며;R33는 Ser,Asn,len,Thr 또는 ala이며 R36는 Lys,Orn,Arg,Har 또는 Len이며;R37은 len 또는 Tyr이며; R38은 Mat 또는 len이며; R|39은 Glu 또는 Asp이며;R1°은 Ile, Thr,Glu,all,Val,len,Nel,Phe,Nva,Gly또는Gln이며;R41는aa,lle,Gly,Val,Len,Nle,Phe,Gln 또는 desR41이며; 단 R38이 Len인 경우 R22는 ala이고/거나 R33은 len이며, 상기 구조식(Ⅱ)에서 X,X1,X2,X3,X4,X5및 X6는 각기 수소이거나 보호기이며 X7은 보호기 또는 수지지지체에 대한 고정결합 또는 OH 또는 NH2이다.
  2. 제1항에 있어서 R9가 Glu인 방법.
  3. 제1항 또는 2항에 있어서 R1이 Glu-Glu이고 R21이 Nle인 방법.
  4. 제1항 내지 3항중 어느 하나에서 R22가 Ala이며, R23이 Arg이며 R38이 Met이며 R41이 Ile인 방법.
  5. 제1항 또는 2항에서 R9이 Glu이고 R33이 Len인 방법.
  6. 제2항 3항 및 5항중 어느 하나에서 R12이 Len이며, R13이 Glu,R22가 Glu이고 R26이 Lys인 방법.
  7. 제1항, 2항, 3항, 5항 및 6항중 어느 하나에서 R29및 R40이 Len인 방법.
  8. 제1-3항 및 5-7항중 어느 하나에서 R27이 Glu이며 R32가 Ala이며 R36이 Len인 방법.
  9. 제1항에 있어서, 하기와 같은 구조식을 갖는 방법.
    H-Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-As-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Met-Leu-Glu-Met-Ala-Lys-Ala-Glu-Gln-Glu-Ala-Glu-Gln-Ala-Ala-Leu-Asn-Arg-Leu-Leu-Leu-Glu-Glu-Ala-NH2
  10. 제1항에 있어서, 하기와 같은 구조식을 갖는 방법.
    H-Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-As-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Ile-NH2
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019840001956A 1983-04-14 1984-04-13 Crf 상사체의 재법 KR900006559B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/484,931 US4489163A (en) 1983-04-14 1983-04-14 rCRF and analogs
US484931 1983-04-14

Publications (2)

Publication Number Publication Date
KR840009075A true KR840009075A (ko) 1984-12-24
KR900006559B1 KR900006559B1 (ko) 1990-09-13

Family

ID=23926236

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840001956A KR900006559B1 (ko) 1983-04-14 1984-04-13 Crf 상사체의 재법

Country Status (16)

Country Link
US (1) US4489163A (ko)
EP (1) EP0122798B1 (ko)
JP (1) JPH0689034B2 (ko)
KR (1) KR900006559B1 (ko)
AT (1) ATE96807T1 (ko)
AU (1) AU565699B2 (ko)
CA (1) CA1247602A (ko)
DE (1) DE3486238T2 (ko)
DK (1) DK172682B1 (ko)
ES (1) ES8606406A1 (ko)
GR (1) GR81467B (ko)
IE (1) IE61617B1 (ko)
IL (1) IL71326A (ko)
NZ (1) NZ207779A (ko)
PH (1) PH23123A (ko)
ZA (1) ZA842460B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3587276T2 (de) * 1984-02-23 1993-07-29 Salk Inst For Biological Studi Crf-analoga.
FR2567524B1 (fr) * 1984-07-10 1987-11-27 Sanofi Sa Procede de synthese de la somatocrinine en phase liquide et peptides intermediaires
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
DE3703340A1 (de) * 1987-02-04 1988-08-18 Dirck Dr Med Oppermann Pharmazeutische zubereitung zur behandlung der herzinsuffizienz
CA1341051C (en) * 1988-09-23 2000-07-11 Jean Edouard Frederic Rivier Crf antagonists
CA1340964C (en) * 1988-09-30 2000-04-18 Jean E. F. Rivier Crf analogs
US5278146A (en) * 1988-09-30 1994-01-11 The Salk Institute For Biological Studies CRF analogs
ZA898329B (en) * 1988-11-14 1990-07-25 Salk Inst For Biological Studi Fish crf
US5488033A (en) * 1989-07-28 1996-01-30 The Regents Of The University Of California Treatment to reduce edema
US5137871A (en) * 1989-07-28 1992-08-11 Regents Of The University Of California Treatment to reduce edema for brain and musculature injuries
DE3942925A1 (de) * 1989-12-23 1991-06-27 Swf Auto Electric Gmbh Elektrischer schalter, insbesondere blinkerschalter fuer kraftfahrzeuge
US5480869A (en) * 1990-01-09 1996-01-02 The Regents Of The University Of California Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues
US5177060A (en) * 1990-01-09 1993-01-05 Regents Of The University Of California Anti-inflammatory peptides and treatment to inhibit vascular leakage in injured tissues
US5235036A (en) * 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
US5245009A (en) * 1990-03-23 1993-09-14 The Salk Institute For Biological Studies CRF antagonists
US5374621A (en) * 1991-09-13 1994-12-20 Regents Of The University Of California Neurotensin method for inhibiting vascular leakage
US5728545A (en) * 1993-06-18 1998-03-17 The Salk Institute Of Biological Studies Cloning and recombinant production of CRF receptor (S)
US6495343B1 (en) 1993-06-18 2002-12-17 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6638905B2 (en) * 1993-06-18 2003-10-28 The Salk Institute For Biological Studies Cloning and recombinant production of CFR receptor(s)
US6039956A (en) * 1994-09-12 2000-03-21 Pennsylvania, Trustees Of The University Of, The Corticotropin release inhibiting factor and methods of using same for treating behavioral symptoms in an anxiety disorder
WO1996008265A1 (en) * 1994-09-12 1996-03-21 The Trustees Of The University Of Pennsylvania Corticotropin release inhibiting factor and methods of using same
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7141546B1 (en) 2001-08-01 2006-11-28 The Salk Institute For Biologicial Studies CRFR2 selective ligands
CA2455223C (en) * 2001-08-01 2010-11-16 The Salk Institute For Biological Studies Crfr1 selective ligands
US20090035298A1 (en) * 2007-04-23 2009-02-05 Washington University In St. Louis Methods to treat alzheimer's disease or other amyloid beta accumulation associated disorders
CN102036680A (zh) * 2008-04-30 2011-04-27 中子行公司 促肾上腺皮质激素释放因子用于治疗癌症的用途
EP2349323A2 (en) 2009-06-24 2011-08-03 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the treatment of cancer
ES2703499T3 (es) 2010-12-22 2019-03-11 Salk Inst Biological Studies Péptidos antagonistas de CRF cíclicos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR67608E (fr) * 1955-02-22 1958-03-14 Variateur de vitesse, notamment pour cycles
GB2016015B (en) 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4415558A (en) 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
EP0094428B1 (en) 1981-11-23 1992-02-12 University Patents, Inc. Control of dna sequence transcription
GB2118190B (en) * 1982-04-13 1985-05-01 Erba Farmitalia Peptides with sauvagine-like activity

Also Published As

Publication number Publication date
KR900006559B1 (ko) 1990-09-13
AU2677784A (en) 1984-10-18
US4489163A (en) 1984-12-18
IL71326A (en) 1987-11-30
NZ207779A (en) 1988-04-29
DE3486238T2 (de) 1994-03-03
ES8606406A1 (es) 1986-04-01
IL71326A0 (en) 1984-06-29
JPS59199662A (ja) 1984-11-12
PH23123A (en) 1989-05-05
EP0122798A3 (en) 1986-09-03
DK169784A (da) 1984-10-15
CA1247602A (en) 1988-12-28
EP0122798A2 (en) 1984-10-24
IE840867L (en) 1984-10-14
GR81467B (ko) 1984-12-11
JPH0689034B2 (ja) 1994-11-09
ATE96807T1 (de) 1993-11-15
AU565699B2 (en) 1987-09-24
DK172682B1 (da) 1999-05-25
EP0122798B1 (en) 1993-11-03
ES531585A0 (es) 1986-04-01
DK169784D0 (da) 1984-03-27
IE61617B1 (en) 1994-11-16
ZA842460B (en) 1984-11-28
DE3486238D1 (de) 1993-12-09

Similar Documents

Publication Publication Date Title
KR840009075A (ko) Crf-상사체의 제법
KR850008681A (ko) 합성펩티드의 제조방법
KR870002163A (ko) 펩티드의 제조방법
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
KR850003417A (ko) 폴리펩티드의 제조방법
WO1995030750A3 (fr) Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
KR840005710A (ko) GnRH 길항질 II
KR850004113A (ko) GnRH 길항물질 제조방법
KR970704461A (ko) Hla 결합 펩티드 및 그의 용도(hla binding peptides and their uses)
KR850001536A (ko) Grf유사체의 제법
NO163959C (no) Fremgangsmaate for utvinning og rensing av et polypeptid.
KR840000477A (ko) 헨테트 라콘타펩티드 crj 및 그 동족체와 관련된 펩티드류의 제조 방법
PT81345A (de) Neue zns-aktive peptide mit wirkung auf das cholinerge system
KR830007516A (ko) 폴리펩타이드 조성물
KR880012643A (ko) 엔카스틴, 이의 제조방법 및 약제로서의 이의 용도
KR840009071A (ko) 펩티드의 제조방법
KR850700246A (ko) Crf 유사체
WO1996023884A3 (en) Human peroxisome proliferator activated receptors
KR860004079A (ko) 성장촉진 펩티드의 제조방법
KR830008997A (ko) 니오신 α 및 그 동족체의 제조방법
ATE17124T1 (de) Polypeptide mit antagonistischen eigenschaften gegenueber der substanz p, verfahren zu ihrer herstellung, deren verwendung und verfahren zum reinigen von polypeptiden.
SE9200144L (sv) Puts- och/eller faergprodukt
WIENEKE et al. The Synthesis of [A19-3-Iodotyrosine] and [A19-3, 5-Diiodotyrosine] insulin (porcine)
KR880013972A (ko) 시상하부 성장 호르몬 방출 요소(hGRF)유사물인 펩타이드
Rock et al. Variant Forms of Factor VIII Procoagulant-Like Material in Haemophiliacs

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030915

Year of fee payment: 14

EXPY Expiration of term